Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05535218
Title Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer (SURE-02)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Claudia Guerrieri

transitional cell carcinoma


Pembrolizumab + Sacituzumab govitecan-hziy

Age Groups: senior | child | adult
Covered Countries ITA

No variant requirements are available.